Early-stage NSCLC Panel

Quick & Concise. Early & Actionable.

Introducing a therapy selection panel designed specifically for your early-stage NSCLC patients, brought to you by the market leader in Oncology Diagnostics for over 20 years.

 

Order Neo's Early Stage NSCLC Panel Now

Why Test EARLY?

Put your patients on a path towards better outcomes – right from the start of their cancer journey.

Current guidelines recommend:

  • Perioperative biomarker testing for all patients with stage IB-IIIA/B NSCLC
  • Considering both stage and known mutations/PD-L1 status when choosing

Personalized oncology intervention immediately after an early-stage diagnosis is possible – but it requires the full picture.

PD-L1 = programmed cell death ligand 1.

Personalized oncology intervention immediately after an early-stage diagnosis is possible – but it requires the full picture.

The Early-stage NSCLC Panel:

  • Offers testing for actionable and informative biomarkers in early-stage NSCLC:
  • Provides a quick and concise but comprehensive overview of actionable information aligned with the latest in emerging clinical evidence
  • Assists in selecting the most appropriate targeted therapies for improved patient outcomes

ALK = anaplastic lymphoma kinase; EGFR = epidermal growth factor receptor; ROS1 = c-ros oncogene 1; PD-L1 = programmed cell death ligand 1.   
* (TAT) Turnaround time is 7 days. Results are integrated into a final comprehensive report.

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients